HealthQuill USFDA
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according to a company statement.
Drugs Health Medical

Merck & Co stops final-stage drug trial for treating PAH

Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.

Read More
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed at a third-party manufacturing facility.
Drugs Health Medical Pharma

FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold

The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.

Read More
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at least two oral antidepressants for treating major depressive disorder.
Uncategorized

J&J’s nasal spray to treat major depressive disorder gets FDA nod

The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.
Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

Read More
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia syndrome (FCS), according to a statement.
Drugs Health Pharma

Ionis Pharma’s drug to treat rare genetic disease gets US regulator’s nod 

The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.

Read More
Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.
Drugs Health Pharma

Cassava’s disputed Alzheimer’s drug flops in end-stage trials

Cassava Sciences Inc., a US-based biotechnology firm, announced its controversial experimental oral molecule to treat Alzheimer’s Disease has failed in last-stage trials.

Read More
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.
Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

Read More
The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a new target date set for March next year.
Drugs Health Pharma

USFDA postpones Organon’s eczema drug review by three months

The US regulator has extended a review of an application by Organon & Co.’s atopic dermatitis (eczema) drug by three months with a.

Read More